BenzingaOctober 22, 2026 at 3:38 AM NY5 Days Ago
B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
